Morgan R A
Clinical Gene Therapy Branch, National Center for Human Genome Research, National Institutes of Health, Bethesda, MD 20892, USA.
Clin Exp Immunol. 1997 Jan;107 Suppl 1:41-4.
HIV-1 is the causative agent of acquired immune deficiency syndrome (AIDS) and is a major international health concern. The limited effectiveness of current antiviral therapies has led to the search for alternative treatments. One emerging field of medical treatment is termed human gene therapy. In principle, human gene therapy calls for the engineering of the cells from a medical patient with an agent that can potentially result in a therapeutic benefit to the patient. It has been suggested that gene therapy technology may be applied as an anti-HIV-1 agent. The term 'intracellular immunization' was suggested for strategies that work within a potential HIV-1 target cell to inhibit the productive infection of that cell by HIV-1. Various strategies based on this intracellular approach have been proposed and include the use of antisense, and transdominant HIV proteins. Both of these approaches can inhibit HIV-1 in vitro and a clinical trial has been proposed to test their effectiveness in vivo.
人类免疫缺陷病毒1型（HIV-1）是获得性免疫缺陷综合征（AIDS）的病原体，是国际上主要的健康关注点。当前抗病毒疗法效果有限，促使人们寻找替代治疗方法。一个新兴的医学治疗领域被称为人类基因疗法。原则上，人类基因疗法要求用一种可能给患者带来治疗益处的制剂对患者的细胞进行改造。有人提出基因治疗技术可用作抗HIV-1制剂。“细胞内免疫”一词用于描述在潜在的HIV-1靶细胞内发挥作用以抑制该细胞被HIV-1有效感染的策略。基于这种细胞内方法已提出了各种策略，包括使用反义技术和显性负性HIV蛋白。这两种方法在体外均能抑制HIV-1，并且已有人提议进行一项临床试验以测试它们在体内的有效性。
